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Abstract
Introduction: Health utilities of tuberculosis (TB) patients may be diminished by side effects from medication, prolonged
treatment duration, physical effects of the disease itself, and social stigma attached to the disease.
Methods: We collected health utility data from Thai patients who were on TB treatment or had been successfully treated for
TB for the purpose of economic modeling. Structured questionnaire and EuroQol (EQ-5D) and EuroQol visual analog scale
(EQ-VAS) instruments were used as data collection tools. We compared utility of patients with two co-morbidities calculated
using multiplicative model (UCAL) with the direct measures and fitted Tobit regression models to examine factors predictive
of health utility and to assess difference in health utilities of patients in various medical conditions.
Results: Of 222 patients analyzed, 138 (62%) were male; median age at enrollment was 40 years (interquartile range [IQR],
35–47). Median monthly household income was 6,000 Baht (187 US$; IQR, 4,000–15,000 Baht [125–469 US$]). Concordance
correlation coefficient between utilities measured using EQ-5D and EQ-VAS (UEQ-5D and UVAS, respectively) was 0.6. UCAL for
HIV-infected TB patients was statistically different from the measured UEQ-5D (p-value,0.01) and UVAS (p-value,0.01). In
tobit regression analysis, factors independently predictive of UEQ-5D included age and monthly household income. Patients
aged $40 years old rated UEQ-5D significantly lower than younger persons. Higher UEQ-5D was significantly associated with
higher monthly household income in a dose response fashion. The median UEQ-5D was highest among patients who had
been successfully treated for TB and lowest among multi-drug resistant TB (MDR-TB) patients who were on treatment.
Conclusions: UCAL of patients with two co-morbidities overestimated the measured utilities, warranting further research of
how best to estimate utilities of patients with such conditions. TB and MDR-TB treatments impacted on patients’ self
perceived health status. This effect diminished after successful treatment.
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Introduction
Tuberculosis (TB) is a severe, often chronic, lung disease causing
nearly nine million illnesses and more than one million deaths
each year. [1] With appropriate treatment, approximately 90% of
patients with active TB disease can be cured, even in patients with
HIV infection. [2,3] Despite the discovery of the first TB drug over
50 years ago, current treatment regimens for susceptible TB still
require the use of a combination of potentially toxic antibiotics for
a minimum of six months to ensure eradication. [4,5] For multi-
drug resistant TB (MDR-TB), available regimens are less potent
(but more noxious), requiring longer treatment durations. [6,7,8]
As such, patients’ health-related quality of life (HRQL), i.e., valued
aspects of life, may be diminished by side effects from medication,
prolonged treatment duration, and in some cultures, social stigma
attached to the disease. [9,10,11] TB disease itself may also have a
negative impact on TB patients’ self perceived health status.
[12,13]
Health systems in Thailand are increasingly cost effective. In an
effort to respond better to patients’ needs, healthcare providers are
integrating services. [14,15,16] Economic and decision analyses
are frequently conducted to inform resource allocation decisions.
HRQL data are widely recognized as an important input in such
exercises, particularly for chronic diseases. [17] HRQL can be
derived using generic and specific instruments. [9] Generic
instruments collect descriptive data and generate health utilities:
preference-based, numeric representations of overall health that
are the most commonly used measures for evaluating HRQL in
economic analyses. [18] While health utilities, as input in cost-
utility analyses, allow comparison between populations and across
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29775diseases, settings, and countries, information generated from
specific instruments focus on problems associated with single
disease states, patient groups, or areas of function and do not allow
broad comparison. [9,18,19]
Our systematic review showed that data on formal assessment
of HRQL in TB patients are rather sparse, particularly in the
Thai setting. To date, there were only two studies conducted in
Thai populations. [20,21] The first study administered a generic
instrument (Medical Outcomes Study 36-Item Short-From
Health Survey) to measure HRQL among 84 pulmonary TB
patients in Yunnan province of China and Southern Thailand.
[20] Findings of this study, however, were published in Chinese,
compromising dissemination of the results to non-Chinese
speaking researchers. In 2008, Kittikraisak et al. conducted a
prospective observational study to evaluate the impact of TB and
HIV treatment on HRQL among 849 TB patients in Thailand.
This study, however, focused on the patients who were HIV-
infected and used a study specific questionnaire to collect HRQL
data. [21] The investigators found impairment in physical and
mental health when Thai HIV-infected patients studied were first
diagnosed with TB. Additionally, completing TB treatment
relieved some physical symptoms, but had little impact on mental
health. Data, however, cannot be used for economic modeling
purposes because neither generic nor specific instruments were
employed to collect data. With increasing interest in identifying
cost-effective interventions that are responsive to patients’ needs,
HRQL data collected using standardized instruments are
urgently needed.
The main purpose of this study was to collect health utility
data, using EuroQol 5D (EQ-5D) and EuroQol visual analogue
scale (EQ-VAS) instruments from Thai TB patients and those
cured or having completed treatment. The data were collected
for use in our economic evaluation analysis of screening and
diagnostic algorithms for pulmonary TB among HIV-infected
patients in Thailand (to be published). In this study, we explored
how socio-demographic characteristics and co-morbidity such as
HIV infection affect TB patients’ health utility and whether
health utilities of patients with different medical conditions were
different. Further, we examined concordance of health utilities
measured using the two instruments. Lastly, we examined
how health utility of patients with two morbidities calculated us-
ing multiplicative approach (UCAL) differed from the measured
utilities.
Methods
Ethics statement
This study was approved by ethical review committees of
Chiang Rai Regional Hospital and Bamrasnaradura Infectious
Diseases Institute. Involvement of Centers for Disease Control and
Prevention (CDC) investigators in this study was determined not to
meet the definition of engagement in human subjects research per
U.S. human subjects research regulations and additional review by
the CDC institutional review board was not required. All
participants had provided written informed consent.
Study setting and population
From August to October 2009, we conducted a cross-sectional
survey and recruited consecutive patients from respective clinics at
Chiang Rai Regional Hospital and Bamrasnaradura Infectious
Diseases Institute. These two hospitals were part of our multi-site
population-based TB surveillance conducted in six provinces in
Thailand and were chosen because they serve a high number of
TB, HIV-infected TB, and HIV patients. [22] Eligible patients
were those diagnosed with TB (including MDR-TB) and/or HIV
$2 weeks before study enrollment to allow time for them to cope
with the diagnosis(es), aged between 18–70 years old, who were
able to communicate in Thai and did not require assistance from
family members regarding communication, were not pregnant,
and were not in the priesthood. Patients with HIV were recruited
regardless of their anti-retroviral therapy (ART) status. After
giving written informed consent, patients were enrolled and
assigned into mutually exclusive groups according to their medical
condition: 1) TB patients receiving TB treatment (TBTX), 2)
MDR-TB patients receiving MDR-TB treatment (MDRTX), 3)
patients who had been successfully treated for TB or MDR-TB
according to World Health Organization definition and finished
treatment for $6 months (anyTBC), 4) HIV-infected patients at any
stage who had not been diagnosed with TB (anyHIV), 5) HIV-
infected TB patients receiving TB treatment (TBTX/HIV), and 6)
HIV-infected patients who had been successfully treated for TB or
MDR-TB and finished treatment for $6 months (anyTBC/HIV).
Sample size that gave 80% power at the 0.05 level of significance
(two-sided) was calculated as specified in the study protocol, with
parameters estimated based on literature. An effect size of 7% for
the difference between utilities of patients in different medical
conditions was used in the calculation. Sample size of 32 patients
per group was required for patients with TB only (groups 1–3). For
HIV-infected patients regardless of TB status (groups 4–6), the
required sample size was 49 per group. For groups 1, 2, and 5, we
restricted enrollment to patients who were on TB or MDR-TB
treatment for $2 weeks at enrollment, a long enough duration to
experience side effect(s) from medications (if any). Each patient
was compensated with 100 Thai Baht (,3US$) for his/her time,
except those in groups 3 and 6 who received additional 400 Baht
for travel expenses because they were no longer visiting the
hospitals for medical care.
Data collection and instruments
At enrollment, trained study nurses administered: 1) structured
questionnaire to collect socio-demographic characteristic data, 2)
EQ-5D, and 3) EQ-VAS instruments (with permission to use from
the developer [the EuroQol Group]) to collect patients’ HRQL
data. The two instruments are recommended by the Thai Health
Technology Assessment Guidelines to be used to value health
utility for economic purposes. [23] EQ-5D consists of five domains
relating to: 1) mobility, 2) self-care, 3) usual activities, 4) pain/
discomfort, and 5) anxiety/depression and was originally used as a
self-administered questionnaire. [24] According to the developer,
it can also be administered and used in postal surveys, in clinics,
and face-to-face interviews. We conducted face to face interview
and for each domain staff asked patients to assess their current
health and respond with one of the following options: ‘‘no
problem’’, ‘‘moderate problem’’, and ‘‘severe problem’’. A color
coded (green, yellow, and red) flip chart was used as a
supplemental tool to enhance patients’ understanding of the
context. An EQ-5D health state of each respondent was recorded.
For example, the ‘‘32211’’ health state implied the patient
perceived a severe problem with mobility, a moderate problem
with self-care and usual activities, but no pain/discomfort or
anxiety/depression. Following EQ-5D administration, we asked
patients to indicate their health status using EQ-VAS. The EQ-
VAS is a standard visual analogue scale including a vertical line,
20 cm in length, anchored at ‘‘0’’ (death) at the bottom and ‘‘100’’
(full health) on top. We asked each patient to mark on the scale a
rating of their health and well-being on the interview day. The
instrument measures an individual’s valuation of their current
overall health status.
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The analysis was divided into four parts. First, we described
socio-demographic and health characteristics. Second, we
calculated EQ-5D utility value (UEQ-5D) by assuming that health
utilities were additive and that the health utility of a person
declined when his/her health deteriorated. [25] We transformed
UEQ-5D from the five-digit coded health states using an additive
formula, including coefficients and a constant derived from the
Thai utility score algorithm established from a recent national
household survey in Thai general population. [26] Theoretically,
UEQ-5D ranges from 0.0 (death) to 1.0 (full health) value scale;
scores less than zero representing states worse than death are
possible. [27] We obtained EQ-VAS utilities (UVAS)b y
transforming them from a 0 to 100 directly to a 0 to 1 scale;
scores lower than zero are not possible. Concordance between
UEQ-5D and UVAS was estimated using ‘‘concord,’’ a user-written
program for Stata by Steichen and Cox. [28,29] Bland-Altman
approach was used to examine agreement between the two scales
used to measure utilities. [30]
Third, we fitted tobit regression models to examine associations
between socio-demographic characteristics and UEQ-5D and UVAS.
We assessed whether there was any difference in health utility
scores of patients in different medical conditions. Tobit regression
models are designed to estimate linear relationships between
variables when there is upper- or lower-censoring in the dependent
variable. [31] We used an upper-censoring limit of one for
analyses of UEQ-5D and UVAS (UEQ-5D and UVAS cannot exceed
one), and a lower limit of zero for analysis of UVAS (UVAS cannot
be lower than zero). The p-value of likelihood ratio chi-square was
used as a guide to the model’s goodness of fit. We used a two sided
p-value of #0.05 to indicate statistical significance. However, to
reduce the chances of a type I error, we employed a Bonferroni’s
adjustment when determining which groups of patients were
different. [32] In this case, a p-value of #0.003 (0.05/15
comparisons) was considered significant. Lastly, we calculated
health utilities of patients with two co-morbidities (e.g., TB and
HIV) using multiplicative formula shown below and compared
them with the actual data measured using EQ-5D and EQ-VAS.
[33] All statistical analyses were conducted using Stata, version 10
(StataCorp LP, College Station, TX, USA).
DW1z2~1{ 1{DW1 ðÞ | 1{DW2 ðÞ
DW
adjusted
2 ~(1{(1{DW1)|(1{DW2)){DW1
~DW2|(1{DW1)
Where health utility (U)=12disability weight (DW )
U
adjusted
2 ~1{(DW2|(1{DW1))
DW, disability weight; U, Health utility; subscript 1 stands for a
more severe condition and subscript 2 stands for a milder
condition.
Results
Socio-demographic characteristics of the population
During the enrollment period, 223 patients with TB and/or
HIV were enrolled in the study. Of these, 222 were analyzed. We
excluded MDRTX/HIV from the analysis because there was only
one patient in this group. The analytic dataset included 32 TBTX,
11 MDRTX,3 2anyTBC,4 9anyHIV, 49 TBTX/HIV, and 49
anyTBC/HIV. Of the 222 patients, 138 (62%) were male, 128
(58%) were married/cohabitating, and 172 (77%) finished either
primary or high school.[Table S1] The median age at enrollment
was 40 years (interquartile range [IQR], 35–47), 79 patients (36%)
were laborers, and 203 (91%) were covered by health insurance.
The median monthly household income was 6,000 Baht (IQR,
4,000–15,000). Among HIV-infected patients, 46 anyHIV (94%),
26 TBTX/HIV (55%), and 38 anyTBC/HIV (100%) reported
currently receiving ART. These patients were diagnosed with and
on treatment for HIV for a median of 36 months (IQR, 18–95)
and 24 months (IQR, 2–51), respectively. TB patients were
diagnosed with TB for a median of 3 months (IQR, 1–5). They
were initiated treatment at the time of diagnosis, resulting in a
median treatment duration of 3 months (IQR, 1–5). MDR-TB
patients were diagnosed with the disease for a median of 9 months
(IQR, 4–11); effective treatment was initiated relatively quickly
after diagnosis. Table 1 shows response of 222 patients to EQ-5D
instrument stratified by medical conditions.
Health utility measured using EQ-5D instrument
UEQ-5D of the 222 patients ranged from 20.02 to 1.0 (median,
0.7; IQR, 0.6–1.0). One of eight MDRTX (9%) perceived his
overall health was worse than death (UEQ-5D, 20.02). This patient
was diagnosed with and had been taking medication for MDR-TB
for 26 months. By contrast, 7 TBTX (22%), 16 anyTBC (50%), 17
anyHIV (35%), 6 TBTX/HIV (12%), and 27 anyTBC/HIV (55%)
perceived they were in full health (UEQ-5D, 1.0). Table 2 shows
median UEQ-5D of the 222 patients stratified by medical
conditions. Overall, the median UEQ-5D was highest among
anyTBC (1.0; IQR, 0.7–1.0) and lowest among MDRTX (0.5; IQR,
0.4–0.7).
Health utility measured using EQ-VAS instrument
The UVAS ranged from 0.0 to 1.0 (median, 0.8; IQR, 0.7–
0.9).[Table 2] The same MDRTX with UEQ-5D of 20.02 rated
his health condition equivalent to death on EQ-VAS. Three TBTX
(9%), 10 anyTBC (31%), 10 anyHIV (20%), 2 TBTX/HIV (4%), and
7 anyTBC/HIV (14%) perceived they were in full health. The
median UVAS was relatively high in all groups of patients, except
MDRTX (0.6; IQR, 0.4–0.8) and TBTX/HIV (0.7; IQR, 0.6–0.8)
whose median scores were slightly lower.
Concordance between UEQ-5D and UVAS
Concordance correlation coefficient between UEQ-5D and UVAS
was 0.6 (95% confidence interval [CI], 0.5–0.7). Twenty-two
patients (10%) rated equivalent health utilities on the two
instruments. Eighty-six patients (39%) rated UEQ-5D higher than
UVAS; 114 patients (51%) rated UEQ-5D lower than UVAS. Bland-
Altman plot in Figure 1 shows the differences between health
utilities measured using EQ-5D and EQ-VAS instruments in
relation to their means. Moderate agreement was observed. The
95% limits of agreement were shown at 20.32 and 0.38. The line
of the average of the observed differences (average bias) was shown
at 0.03.
Predictors of health utility
In tobit regression analysis, factors independently predictive of
UEQ-5D included age and monthly household income.[Table 3]
Patients aged $40 years old rated UEQ-5D significantly lower than
those aged ,40 years old, adjusting for medical condition and
monthly household income (estimate, 20.08; CI, 20.14 to
20.004). We found a dose response effect when examining
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household income $5,000 Thai Baht rated UEQ-5D significantly
higher than patients with lower income, adjusting for medical
condition and age.[Table 3] In the analysis of UVAS, we did not
find any factor predictive of UVAS.
Difference in health utility
We found that UEQ-5D were highest in anyTBC, followed by
anyTBC/HIV, anyHIV, TBTX,T B TX/HIV, and MDRTX, adjust-
ing for age and monthly household income. With Bonferroni’s
adjustment, patients could be divided, according to the fitted
Table 2. Health utilities of 222 Thai patients with various medical conditions measured using EuroQol 5D and EuroQol visual
analogue score instruments, August to October 2009.
Patients TB treatment
% receiving anti-
retroviral therapy N Health utility by instrument
Median EQ-5D (IQR) SD
Median EQ-VAS
(IQR) SD
TB On TB treatment Not applicable 32 0.69 (0.57–0.77) 0.22 0.80 (0.70–0.90) 0.15
MDR-TB On MDR-TB treatment Not applicable 11 0.51 (0.39–0.73) 0.21 0.60 (0.40–0.80) 0.25
TB or MDR-TB Cured or completed
treatment
Not applicable 32 0.88 (0.67–1.00) 0.17 0.85 (0.80–1.00) 0.15
HIV Not applicable 94% 49 0.73 (0.63–1.00) 0.19 0.80 (0.70–0.90) 0.15
TB with HIV On TB treatment 55% 49 0.67 (0.57–0.73) 0.16 0.70 (0.60–0.80) 0.16
TB or MDR-TB with
HIV
Cured or completed
treatment
100% 49 1.00 (0.69–1.00) 0.18 0.80 (0.70–0.90) 0.14
222 0.73 (0.62–1.00) 0.21 0.80 (0.70–0.90) 0.17
TB, tuberculosis; MDR-TB, multi-drug resistant tuberculosis; EQ-5D, EuroQol 5D instrument; EQ-VAS, EuroQol visual analogue scale instrument; IQR, interquartile range;
SD, standard deviation.
doi:10.1371/journal.pone.0029775.t002
Table 1. Response of 222 Thai patients with various medical conditions to EuroQol 5D instrument, August to October 2009.
All (n=222) TBTX (n=32)
MDRTX
(n=11)
anyTBC
(n=32)
anyHIV
(n=49) TBTX/HIV (n=49) anyTBC/HIV (n=49)
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Mobility
No problem 172 (77) 21 (66) 5 (45) 28 (88) 41 (84) 32 (65) 45 (92)
Moderate problem 50 (23) 11 (34) 6 (55) 4 (12) 8 (16) 17 (35) 4 (8)
Severe problem 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Self care
No problem 210 (95) 26 (81) 9 (82) 32 (100) 48 (98) 47 (96) 48 (98)
Moderate problem 12 (5) 6 (19) 2 (18) 0 (0) 1 (2) 2 (4) 1 (2)
Severe problem 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Usual activities
No problem 161 (73) 22 (69) 3 (27) 29 (91) 40 (82) 26 (53) 41 (84)
Moderate problem 57 (26) 9 (28) 6 (55) 3 (9) 9 (18) 22 (45) 8 (16)
Severe problem 4 (1.8) 1 (3) 2 (18) 0 (0) 0 (0) 1 (2) 0 (0)
Pain/discomfort
No problem 95 (43) 10 (31) 0 (0) 18 (56) 23 (47) 12 (24) 32 (65)
Moderate problem 122 (55) 21 (66) 9 (82) 14 (44) 25 (51) 36 (73) 17 (35)
Severe problem 5 (2) 1 (3) 2 (18) 0 (0) 1 (2) 1 (2) 0 (0)
Anxiety/depression
No problem 125 (56) 15 (47) 3 (27) 25 (78) 27 (55) 23 (47) 32 (65)
Moderate problem 93 (42) 17 (53) 7 (64) 7 (22) 20 (41) 26 (53) 16 (33)
Severe problem 4 (2) 0 (0) 1 (9) 0 (0) 2 (4) 0 (0) 1 (2)
TBTX, TB patients receiving TB treatment; MDRTX, MDR-TB patients receiving MDR-TB treatment; anyTBC, patients who had been successfully treated for TB or MDR-TB for
$6 months; anyHIV, HIV-infected patients at any stage; TBTX/HIV, HIV-infected TB patients receiving TB treatment; anyTBC/HIV, HIV-infected patients who had been
successfully treated for TB or MDR-TB for $6 months.
doi:10.1371/journal.pone.0029775.t001
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anyTBC/HIV, anyHIV; 2) anyHIV, TBTX,T B TX/HIV; and 3)
TBTX,T B TX/HIV, MDRTX. Figure 2 shows estimated
differences in health utilities of patients with various medical
conditions, adjusting for age and monthly household income. In
the analysis of UVAS, we found that UVAS of patients in different
groups ranked in the same order as that seen in the analysis of
UEQ-5D. However, because the model fitted poorly we did not
further examine if and how each group of patients differed from
one another.
Figure 1. Bland-Altman plot showing the differences between health utilities measured using EuroQol 5D and EuroQol visual
analogue scale instruments in relation to the mean of the two measurements in the 222 Thai patients, August to October 2009.
doi:10.1371/journal.pone.0029775.g001
Table 3. Multivariate tobit regression analysis examining determinants of health utility of 222 Thai patients measured using
EuroQol 5D instrument, August to October 2009.
Estimates 95% confidence interval p-value
Lower Upper
Patient group
TBTX 20.24 20.37 20.10 ,0.01
MDRTX 20.41 20.58 20.24 ,0.01
anyTBC ref ref ref
anyHIV 20.13 20.26 0.01 0.04
TBTX/HIV 20.27 20.39 20.15 ,0.01
anyTBC/HIV 20.01 20.14 0.13 0.93
Age group (years)
,40 ref ref ref
$40 20.08 20.15 20.003 0.04
Monthly household income
(Thai Baht)
*
,5,000 ref ref ref
5,000–9,999 0.09 0.004 0.17 0.04
10,000–19,999 0.13 0.03 0.23 0.01
$20,000 0.17 0.06 0.28 ,0.01
TB, tuberculosis; MDR-TB, multi-drug resistant tuberculosis; TBTX, TB patients receiving TB treatment; MDRTX, MDR-TB patients receiving MDR-TB treatment; anyTBC,
patients who had been successfully treated for TB or MDR-TB for $6 months; anyHIV, HIV-infected patients at any stage; TBTX/HIV, HIV-infected TB patients receiving TB
treatment; anyTBC/HIV, HIV-infected patients who had been successfully treated for TB or MDR-TB for $6 months; ref, referent group.
*32 Thai Baht=1 US$.
doi:10.1371/journal.pone.0029775.t003
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The median health utility of 49 TBTX/HIV was relatively high
(0.7 for both UEQ-5D and UVAS). UCAL for patients with TB and
HIV co-infection (0.8) was statistically different from the measured
UEQ-5D (p,0.01), and UVAS (p,0.01). Of the 49 TBTX/HIV, 43
(88%) rated UEQ-5D lower than UCAL. Six (12%) rated UEQ-5D
higher than UCAL. None of TBTX/HIV rated UEQ-5D equal to
UCAL. Likewise, 31 patients (63%) rated UVAS lower than UCAL.
Nine (18%) rated UVAS higher than UCAL. Nine patients (18%)
rated UVAS equal to UCAL.
Discussion
In this study, we found that the Thai language EQ-5D and EQ-
VAS instruments could be used for measuring and evaluating
health utility in a selected group of TB and HIV patients. Further,
patients’ age and monthly household income were found to be
determinants of UEQ-5D. TB and MDR-TB treatment may impact
health utilities of patients receiving such treatment. This effect
diminished after successful treatment of the disease. Health utilities
of patients with HIV and TB calculated using multiplicative model
for two co-morbidities overestimated the directly measured
utilities.
To our knowledge, this is the first study that elicited health
utility in HIV-infected TB patients and compared health utilities
between HIV-infected and HIV-uninfected TB patients. Our
study is also the first study demonstrating feasibility of the Thai
language EQ-5D and EQ-VAS instruments in measuring health
utility in a Thai TB population regardless of HIV-infection. The
English versions of the instruments were recommended for use in
all groups of patients and the Thai versions have recently been
ratified by the EuroQol Group’s Translation Committee. [34,35]
Both instruments could identify differences in health utilities
among patients with different medical conditions. In this study,
more than half were elderly or adults with co-morbidity who had
finished basic schooling. All successfully completed the study task
using the EQ-5D and EQ-VAS. We believe that this would not be
possible with the original English language self-administered
instruments. It should be noted that assistance from study
personnel was only to read questions on instruments to
participants who had difficulty reading. Color-coded supplemental
tool was used to help participants who had trouble remembering
answer choices. Further, a study by Puhan et al has documented
that administration formats do not have a meaningful effect on
repeated measurements of patient-reported HRQL outcomes. [36]
While our study was conducted among a sample of TB patients,
the socio-demographic and health characteristics of our popula-
tion were similar to those of the population-based TB surveillance
network in Thailand. This suggests our findings may be
generalisable to the wider Thai TB population. [22,37]
Consistent with previously studies, higher HRQL, the UEQ-5D
in our study, was correlated with younger age and higher
household income, likely because of better prognosis. [12,38,
39,40] Yet, we did not find significant associations between sex,
education, health insurance coverage, and HRQL as found in
other studies or any predictor for UVAS. [39,41] This may be due
to different characteristics of the populations studied. Our
population was out-patients receiving services at hospitals and
more than 90% were covered by health insurance. In contrast,
those in Duyan’s study were hospitalized TB patients with low
levels of education and no social insurance coverage. [39]
Additionally, those in both Duyan’s and Nyamathi’s studies
reported insufficient housing conditions. [39,41]
The UEQ-5D and UVAS obtained from this study were in line
with other studies which suggested that impaired health utility
occurred during TB and MDR-TB treatments. [21,38,42] Nearly
half of our TB patients were still in the intensive phase of TB
treatment, making them more prone to disutility. Moreover, 63%
of MDR-TB had been on treatment for more than six months with
one patient being on treatment for more than two years. This
finding together with those from our previous study suggests that
provision of a more holistic approach to medical care not limited
only to HIV and TB treatment may be beneficial to the patients.
[21] Interventions focusing on symptom management and
coordination of care may help relieve symptoms and improve
patients’ ability to tolerate medical treatment as well as help them
gain the strength to carry on with daily life. In this study, we also
found that improved health utility after TB treatment was more
pronounced in HIV-infected patients than those uninfected in
nearly all domains. This is likely due to relief of some TB
symptoms and adverse events from HIV and TB drug interactions.
[21,43] Our study did not measure markers of disease progression
(e.g., CD4+ T-lymphocyte) among those HIV-infected. Nonethe-
less, studies have reported that HIV-infected patients with or
Figure 2. Schematic diagram showing estimated difference in health utilities of 222 Thai patients with various medical conditions
adjusting for age and monthly household income and measured using EuroQol 5D instrument, August to October 2009.
doi:10.1371/journal.pone.0029775.g002
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of highly active ART. This could likely be explained by the
effectiveness of medication in reversing the progression of disease
in individuals with AIDS and accommodation to the stress of living
with the disease. [44,45] In fact, over 80% of HIV-infected
patients in our study were receiving ART and were among those
whose UEQ-5D were highest. This finding implies that ART
delivery in the public sector of Thai healthcare system may have
an impact not only on patients’ survival as has been found in other
studies, but also HRQL and ability to function in society.
[46,47,48]
It is noteworthy that health utilities of persons with two co-
morbidities calculated using multiplicative model were overesti-
mated compared to those measured directly using EQ-5D and
EQ-VAS. Because co-morbidities are common, this finding
warrants further research of how best to estimate utilities of
patients with such conditions.
There are a number of limitations in our study. First, enrollment
of patients was not done in a random or systematic manner due to
operational constraints. As mentioned, socio-demographic and
health characteristics of our patients were similar to those in a
multi-site population-based TB surveillance system, suggesting
interviewed patients may be broadly representative. Second, there
was only one MDRTX/HIV enrolled in our study; this patient was
subsequently excluded from the analysis because of small sample
size. This implies the rarity of this sub-population in Thailand.
HRQL in this particular group remains an open question that
needs to be addressed by future research in settings where
MDRTX/HIV is more prevalent. Further, the required sample
size for MDRTX was not met, prompting caution when
interpreting data of this particular group of patients. Third, we
did not further stratify patients based on sputum smear microscopy
results because of the restriction to enrol only patients who had
received TB treatment for $2 weeks. Some of these patients were
expected to have a conversion by the interview time. In India,
Dhingra and Rajpal have documented difference in HRQL
between smear positive and negative TB patients using a TB-
specific instrument. [49] We were unable to investigate if this
difference existed in our study. Fourth, screening for active TB
among our HIV-infected patients may not have been optimal. It is
possible that some patients may have had undiagnosed TB,
resulting in misclassification. However, patients in our study were
routinely asked if they had coughed along with other symptoms.
This information was passed to attending physicians. Therefore,
we believe that number of undiagnosed TB should be small.
Lastly, as for other HRQL instruments, the EQ-5D and EQ-VAS
reflect patients’ opinions. Different individuals assign different
values to the same health state, and consequently vary in their
preferences. Further, as pointed out by Aghakhani et al, the overall
responses to the EQ-5D instrument (which has three possible
answers) may be forced to the mid-range category because few
patients endorse the ‘severe’ value and some limitation is often
present. This possibly results in diverting responses away from the
‘no limitation’ option. [50] The EQ-5D has been critiqued as less
sensitive than disease-specific measurements resulting in possible
overestimation of patients’ HRQL. Nonetheless, because one of
the study goals was to identify utility values that could be used for
economic modelling in the future, the ability to compare across
diseases outweighed the sensitivity concerns.
In resource-limited settings, economic analysis is increasingly
carried out to inform practice guidelines, funding decisions, and
research initiatives. Utility data collected from our study may be
incorporated into cost-effectiveness and cost-utility analyses. These
in turn allow TB control strategies to be compared more directly
with other public health interventions, with respect to both costs
and consequences and whether the interventions are of benefit in
relation to HRQL. Our findings also suggest that the EQ-5D and
EQ-VAS have discriminative power and are responsive to
clinically important changes related to TB treatment.
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